Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options for the other subtypes have also improved. The evidence base for what is currently the only immunomodulatory therapy for primary chronic progressive MS (PPMS) has recently been expanded by several new studies.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Efficacy, safety and practical application
Phytotherapeutic options for endometriosis
- Anxiety disorders
New study on lavender oil extract in a long-term setting
- Evidence, effectiveness and practical implications
Medicinal plants for allergic rhinitis
- Current status and future prospects
Cell and gene therapies in modern cardiology
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer